Abstract 4572: 3D-EXpress ex vivo platform using a biorepository of characterized fresh patient tumoroids allows development of rational combinations with drugs targeting DNA damage response and immune checkpoint blockade
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-4572
Abstract: Introduction: Nilogen Oncosystems’ 3D-EXpress platform allows for the detailed characterization offreshly resected patient tumor tissue for inclusion in studies investigating rational combinations of IOtherapeutics. Incorporating data on immune cell composition, tumor cell target expression, mutationalstatus,… read more here.
Keywords: targeting dna; platform; dna damage; tumor ... See more keywords
Abstract SY32-03: Overcoming PARP inhibitor resistance through rational combinations in the clinic
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-sy32-03
Abstract: Genomic instability is a key hallmark of cancer that arises owing to defects in the DNA damage response (DDR) and/or increased replication stress. The therapeutic landscape of antitumor agents targeting the DDR has rapidly expanded… read more here.
Keywords: resistance rational; inhibitor resistance; parp inhibitor; overcoming parp ... See more keywords
Rational combinations of immunotherapy for pancreatic ductal adenocarcinoma.
Sign Up to like & getrecommendations! Published in 2017 at "Chinese clinical oncology"
DOI: 10.21037/cco.2017.06.04
Abstract: The complex interaction between the immune system, the tumor and the microenvironment in pancreatic ductal adenocarcinoma (PDA) leads to the resistance of PDA to immunotherapy. To overcome this resistance, combination immunotherapy is being proposed. However,… read more here.
Keywords: combinations immunotherapy; rational combinations; immunotherapy pancreatic; pancreatic ductal ... See more keywords